皮肤毒性蚂蚁抗EGFR治疗：老年人和体弱Mcrc患者的一个模拟问题

Annals of hematology & oncology Pub Date : 2018-10-01 DOI:10.26420/annhematoloncol.2018.1213

R. Addeo

{"title":"皮肤毒性蚂蚁抗EGFR治疗：老年人和体弱Mcrc患者的一个模拟问题","authors":"R. Addeo","doi":"10.26420/annhematoloncol.2018.1213","DOIUrl":null,"url":null,"abstract":"prognosis and survival. co morbidity advanced most clinical trials sufficient on the appropriate management of elderly patients with metastatic CRC. The development of new therapeutic agents bevacizumab (anti-VRGF) and cetuximab panitumumab (anti-Epidermal Growth Factor Receptor (EGFR)) which target specific molecular events in tumour cells provides new opportunities to improve the treatment of this type of cancer.","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Skin Toxicity Ant Anti-EGFR-Therapy: A Mock Trouble for Elderly and Frail Patients with Mcrc\",\"authors\":\"R. Addeo\",\"doi\":\"10.26420/annhematoloncol.2018.1213\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"prognosis and survival. co morbidity advanced most clinical trials sufficient on the appropriate management of elderly patients with metastatic CRC. The development of new therapeutic agents bevacizumab (anti-VRGF) and cetuximab panitumumab (anti-Epidermal Growth Factor Receptor (EGFR)) which target specific molecular events in tumour cells provides new opportunities to improve the treatment of this type of cancer.\",\"PeriodicalId\":72219,\"journal\":{\"name\":\"Annals of hematology & oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of hematology & oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26420/annhematoloncol.2018.1213\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hematology & oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/annhematoloncol.2018.1213","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

预后和生存率。合并发病率推进了大多数临床试验，这些试验足以对患有转移性CRC的老年患者进行适当的管理。靶向肿瘤细胞中特定分子事件的新治疗剂贝伐单抗（抗VRGF）和西妥昔单抗帕尼妥单抗（抗表皮生长因子受体（EGFR））的开发为改善这类癌症的治疗提供了新的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Skin Toxicity Ant Anti-EGFR-Therapy: A Mock Trouble for Elderly and Frail Patients with Mcrc

prognosis and survival. co morbidity advanced most clinical trials sufficient on the appropriate management of elderly patients with metastatic CRC. The development of new therapeutic agents bevacizumab (anti-VRGF) and cetuximab panitumumab (anti-Epidermal Growth Factor Receptor (EGFR)) which target specific molecular events in tumour cells provides new opportunities to improve the treatment of this type of cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of hematology & oncology

自引率

0.00%

发文量